ReviewRSC advances2025
Developing point-of-need (PON) cancer biosensors using microfluidic paper-based analytical devices: recent advances.
Review in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microfluidic paper-based analytical devices (µPADs) are considered a key solution as they offer a low-cost platform for developing point-of-need (PON) biosensors for cancer biomarker/cell detection. Nanomaterials utilized in the structures of µPADs and PADs provide powerful tools for the early-stage diagnosis of cancer. This review aims to summarize the recent advances in a variety of µPADs and PADs used for cancer diagnosis based on different types of nanomaterials, such as metal/metal oxide nanoparticles, magnetic nanoparticles, quantum dots, and 1-3 dimensional materials. This review also discusses the properties and functions of various nanomaterials, highlighting their recent applications in PAD- and µPAD-based diagnosis of cancer biomarkers and cells based on immune-, apta-, geno-, peptide-, and enzymatic-biosensing. Additionally, the critical role of detection techniques, like electrochemical, optical (UV-Vis spectrophotometry, SPR, SERS, and fluorometry), electrochemiluminescent, photoelectrochemical, and piezoelectric methods, in label-free and labeled bio-assays of cancer biomarkers are surveyed. The advantages and limitations of various sensing methods, techniques, types of materials and fabrication strategies are surveyed to explore the best cases for cancer diagnosis using PADs and µPADs. The roles of novel technologies such as AI and IOT, in the development of PAD- and µPAD-based cancer diagnosis are investigated. Finally, a comparison of the advantages and limitations of PADs and µPADs in the early-stage diagnosis of various cancers is reviewed towards exploring the research/technological gaps.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.